<!doctype html><html><head><title>Amyloidosis NEJM</title><base href="../"><meta id="root-path" root-path="../"><link rel="icon" sizes="96x96" href="https://publish-01.obsidian.md/access/f786db9fac45774fa4f0d8112e232d67/favicon-96x96.png"><meta name="viewport" content="width=device-width,initial-scale=1,user-scalable=yes,minimum-scale=1,maximum-scale=5"><meta charset="UTF-8"><link rel="stylesheet" href="lib/styles/obsidian-styles.css"><link rel="stylesheet" href="lib/styles/theme.css"><link rel="stylesheet" href="lib/styles/plugin-styles.css"><link rel="stylesheet" href="lib/styles/snippets.css"><link rel="stylesheet" href="lib/styles/generated-styles.css"><style></style><script type="module" src="lib/scripts/graph_view.js"></script><script src="lib/scripts/graph_wasm.js"></script><script src="lib/scripts/tinycolor.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/pixi.js/7.2.4/pixi.min.js" integrity="sha512-Ch/O6kL8BqUwAfCF7Ie5SX1Hin+BJgYH4pNjRqXdTEqMsis1TUYg+j6nnI9uduPjGaj7DN4UKCZgpvoExt6dkw==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><script src="lib/scripts/webpage.js"></script><script src="lib/scripts/generated.js"></script></head><body class="theme-light show-inline-title loading"><div class="webpage-container"><div class="sidebar-left sidebar"><div class="sidebar-container"><div class="sidebar-sizer"><div class="sidebar-content-positioner"><div class="sidebar-content"><div><label class="theme-toggle-container" for="theme_toggle"><input class="theme-toggle-input" type="checkbox" id="theme_toggle"><div class="toggle-background"></div></label></div><div class="tree-container file-tree mod-nav-indicator" data-depth="0"><div class="tree-header"><span class="sidebar-section-header">Notes</span><button class="clickable-icon collapse-tree-button is-collapsed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></svg></button></div><div class="tree-scroll-area"><div class="tree-item mod-tree-folder mod-collapsible is-collapsed" data-depth="1"><div class="tree-item-contents"><a class="internal-link tree-item-link"><div class="tree-item-icon collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon right-triangle"><path d="M3 8L12 17L21 8"></path></svg></div><span class="tree-item-title">Plasma Cell Disorders</span></a></div><div class="tree-item-children" style="display:none"><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/active-multiple-myeloma.html"><span class="tree-item-title">Active Multiple Myeloma</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/al-amyloidosis.html"><span class="tree-item-title">AL Amyloidosis</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/amyloidosis-nejm.html"><span class="tree-item-title">Amyloidosis NEJM</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/amyloidosis_-general.html"><span class="tree-item-title">Amyloidosis_ general</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/mgus-monoclonal-gammopathy-of-undetermined-signi.html"><span class="tree-item-title">MGUS - Monoclonal Gammopathy of Undetermined Signi</span></a></div><div class="tree-item-children"></div></div><div class="tree-item mod-tree-file" data-depth="2"><div class="tree-item-contents"><a class="internal-link tree-item-link" href="plasma-cell-disorders/monoclonal-gammopathy-disorders-(fellow).html"><span class="tree-item-title">Monoclonal Gammopathy Disorders (Fellow)</span></a></div><div class="tree-item-children"></div></div></div></div></div></div></div></div></div></div><div class="sidebar-gutter"><div class="clickable-icon sidebar-collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><path d="M21 3H3C1.89543 3 1 3.89543 1 5V19C1 20.1046 1.89543 21 3 21H21C22.1046 21 23 20.1046 23 19V5C23 3.89543 22.1046 3 21 3Z"></path><path d="M10 4V20"></path><path d="M4 7H7"></path><path d="M4 10H7"></path><path d="M4 13H7"></path></svg></div></div></div><div class="document-container show"><div class="markdown-preview-view markdown-rendered node-insert-event allow-fold-headings show-indentation-guide allow-fold-lists show-properties" style="tab-size:4"><style id="MJX-CHTML-styles">mjx-container[jax=CHTML]{line-height:0}mjx-container [space="1"]{margin-left:.111em}mjx-container [space="2"]{margin-left:.167em}mjx-container [space="3"]{margin-left:.222em}mjx-container [space="4"]{margin-left:.278em}mjx-container [space="5"]{margin-left:.333em}mjx-container [rspace="1"]{margin-right:.111em}mjx-container [rspace="2"]{margin-right:.167em}mjx-container [rspace="3"]{margin-right:.222em}mjx-container [rspace="4"]{margin-right:.278em}mjx-container [rspace="5"]{margin-right:.333em}mjx-container [size="s"]{font-size:70.7%}mjx-container [size=ss]{font-size:50%}mjx-container [size=Tn]{font-size:60%}mjx-container [size=sm]{font-size:85%}mjx-container [size=lg]{font-size:120%}mjx-container [size=Lg]{font-size:144%}mjx-container [size=LG]{font-size:173%}mjx-container [size=hg]{font-size:207%}mjx-container [size=HG]{font-size:249%}mjx-container [width=full]{width:100%}mjx-box{display:inline-block}mjx-block{display:block}mjx-itable{display:inline-table}mjx-row{display:table-row}mjx-row>*{display:table-cell}mjx-mtext{display:inline-block;text-align:left}mjx-mstyle{display:inline-block}mjx-merror{display:inline-block;color:red;background-color:#ff0}mjx-mphantom{visibility:hidden}mjx-assistive-mml{top:0;left:0;clip:rect(1px,1px,1px,1px);user-select:none;position:absolute!important;padding:1px 0 0!important;border:0!important;display:block!important;width:auto!important;overflow:hidden!important}mjx-assistive-mml[display=block]{width:100%!important}mjx-math{display:inline-block;text-align:left;line-height:0;text-indent:0;font-style:normal;font-weight:400;font-size:100%;letter-spacing:normal;border-collapse:collapse;overflow-wrap:normal;word-spacing:normal;white-space:nowrap;direction:ltr;padding:1px 0}mjx-container[jax=CHTML][display=true]{display:block;text-align:center;margin:1em 0}mjx-container[jax=CHTML][display=true][width=full]{display:flex}mjx-container[jax=CHTML][display=true] mjx-math{padding:0}mjx-container[jax=CHTML][justify=left]{text-align:left}mjx-container[jax=CHTML][justify=right]{text-align:right}mjx-c{display:inline-block}mjx-utext{display:inline-block;padding:.75em 0 .2em}mjx-mi{display:inline-block;text-align:left}mjx-msub{display:inline-block;text-align:left}mjx-mn{display:inline-block;text-align:left}mjx-mo{display:inline-block;text-align:left}mjx-stretchy-h{display:inline-table;width:100%}mjx-stretchy-h>*{display:table-cell;width:0}mjx-stretchy-h>*>mjx-c{display:inline-block;transform:scaleX(1)}mjx-stretchy-h>*>mjx-c::before{display:inline-block;width:initial}mjx-stretchy-h>mjx-ext{overflow:clip visible;width:100%}mjx-stretchy-h>mjx-ext>mjx-c::before{transform:scaleX(500)}mjx-stretchy-h>mjx-ext>mjx-c{width:0}mjx-stretchy-h>mjx-beg>mjx-c{margin-right:-.1em}mjx-stretchy-h>mjx-end>mjx-c{margin-left:-.1em}mjx-stretchy-v{display:inline-block}mjx-stretchy-v>*{display:block}mjx-stretchy-v>mjx-beg{height:0}mjx-stretchy-v>mjx-end>mjx-c{display:block}mjx-stretchy-v>*>mjx-c{transform:scaleY(1);transform-origin:left center;overflow:hidden}mjx-stretchy-v>mjx-ext{display:block;height:100%;box-sizing:border-box;border:0 solid transparent;overflow:visible clip}mjx-stretchy-v>mjx-ext>mjx-c::before{width:initial;box-sizing:border-box}mjx-stretchy-v>mjx-ext>mjx-c{transform:scaleY(500) translateY(.075em);overflow:visible}mjx-mark{display:inline-block;height:0}mjx-c::before{display:block;width:0}.MJX-TEX{font-family:MJXZERO,MJXTEX}.TEX-B{font-family:MJXZERO,MJXTEX-B}.TEX-I{font-family:MJXZERO,MJXTEX-I}.TEX-MI{font-family:MJXZERO,MJXTEX-MI}.TEX-BI{font-family:MJXZERO,MJXTEX-BI}.TEX-S1{font-family:MJXZERO,MJXTEX-S1}.TEX-S2{font-family:MJXZERO,MJXTEX-S2}.TEX-S3{font-family:MJXZERO,MJXTEX-S3}.TEX-S4{font-family:MJXZERO,MJXTEX-S4}.TEX-A{font-family:MJXZERO,MJXTEX-A}.TEX-C{font-family:MJXZERO,MJXTEX-C}.TEX-CB{font-family:MJXZERO,MJXTEX-CB}.TEX-FR{font-family:MJXZERO,MJXTEX-FR}.TEX-FRB{font-family:MJXZERO,MJXTEX-FRB}.TEX-SS{font-family:MJXZERO,MJXTEX-SS}.TEX-SSB{font-family:MJXZERO,MJXTEX-SSB}.TEX-SSI{font-family:MJXZERO,MJXTEX-SSI}.TEX-SC{font-family:MJXZERO,MJXTEX-SC}.TEX-T{font-family:MJXZERO,MJXTEX-T}.TEX-V{font-family:MJXZERO,MJXTEX-V}.TEX-VB{font-family:MJXZERO,MJXTEX-VB}mjx-stretchy-h mjx-c,mjx-stretchy-v mjx-c{font-family:MJXZERO,MJXTEX-S1,MJXTEX-S4,MJXTEX,MJXTEX-A!important}@font-face{font-family:MJXZERO;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Zero.woff") format("woff")}@font-face{font-family:MJXTEX;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Main-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-B;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Main-Bold.woff") format("woff")}@font-face{font-family:MJXTEX-I;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Math-Italic.woff") format("woff")}@font-face{font-family:MJXTEX-MI;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Main-Italic.woff") format("woff")}@font-face{font-family:MJXTEX-BI;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Math-BoldItalic.woff") format("woff")}@font-face{font-family:MJXTEX-S1;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Size1-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-S2;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Size2-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-S3;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Size3-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-S4;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Size4-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-A;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_AMS-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-C;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Calligraphic-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-CB;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Calligraphic-Bold.woff") format("woff")}@font-face{font-family:MJXTEX-FR;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Fraktur-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-FRB;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Fraktur-Bold.woff") format("woff")}@font-face{font-family:MJXTEX-SS;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_SansSerif-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-SSB;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_SansSerif-Bold.woff") format("woff")}@font-face{font-family:MJXTEX-SSI;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_SansSerif-Italic.woff") format("woff")}@font-face{font-family:MJXTEX-SC;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Script-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-T;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Typewriter-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-V;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Vector-Regular.woff") format("woff")}@font-face{font-family:MJXTEX-VB;src:url("https://publish.obsidian.md/lib/mathjax/output/chtml/fonts/woff-v2/MathJax_Vector-Bold.woff") format("woff")}mjx-c.mjx-c31::before{padding:.666em .5em 0 0;content:"1"}mjx-c.mjx-c1D45F.TEX-I::before{padding:.442em .451em .011em 0;content:"r"}mjx-c.mjx-c5C::before{padding:.75em .5em .25em 0;content:"\\"}mjx-c.mjx-c51::before{padding:.705em .778em .193em 0;content:"Q"}mjx-c.mjx-c1D45D.TEX-I::before{padding:.442em .503em .194em 0;content:"p"}mjx-c.mjx-c3D::before{padding:.583em .778em .082em 0;content:"="}mjx-c.mjx-c1D43A.TEX-I::before{padding:.705em .786em .022em 0;content:"G"}mjx-c.mjx-c1D438.TEX-I::before{padding:.68em .764em 0 0;content:"E"}mjx-c.mjx-c29::before{padding:.75em .389em .25em 0;content:")"}mjx-c.mjx-cA0::before{padding:0 .25em 0 0;content:" "}mjx-c.mjx-c1D454.TEX-I::before{padding:.442em .477em .205em 0;content:"g"}mjx-c.mjx-c1D439.TEX-I::before{padding:.68em .749em 0 0;content:"F"}mjx-c.mjx-c1D43C.TEX-I::before{padding:.683em .504em 0 0;content:"I"}mjx-c.mjx-c1D43D.TEX-I::before{padding:.683em .633em .022em 0;content:"J"}</style><div class="markdown-preview-sizer markdown-preview-section" style="min-height:26997px"><div class="markdown-preview-pusher" style="width:1px;height:.1px;margin-bottom:0"></div><div class="mod-header"><div class="inline-title" data-heading="Amyloidosis NEJM" id="Amyloidosis_NEJM" style="display:block">Amyloidosis NEJM</div></div><div><pre class="frontmatter language-yaml" tabindex="0" style="display:none"><code class="language-yaml is-loaded"><span class="token key atrule">title</span><span class="token punctuation">:</span> Amyloidosis NEJM
<span class="token key atrule">updated</span><span class="token punctuation">:</span> <span class="token datetime number">2021-09-16 15:26:37Z</span>
<span class="token key atrule">created</span><span class="token punctuation">:</span> <span class="token datetime number">2021-01-28 03:32:00Z</span>
<span class="token key atrule">author</span><span class="token punctuation">:</span> inna.gong@gmail.com
<span class="token key atrule">latitude</span><span class="token punctuation">:</span> <span class="token number">43.72305933</span>
<span class="token key atrule">longitude</span><span class="token punctuation">:</span> <span class="token number">-79.38026075</span>
<span class="token key atrule">altitude</span><span class="token punctuation">:</span> <span class="token number">149.2391</span></code><button class="copy-code-button">Copy</button></pre></div><div><p>Briefly, the patient presented otherwise well to clinic endorsing 2 years of mild dyspnea when climbing stairs but with unlimited exercise tolerance on flat ground. He denied chest pain, leg swelling, orthopnea, fatigue, or f/c/s. He had a 20 pack-year smoking history, with no other drug use or inhalational use, and no known occupational or home exposures. The patient’s cardiopulmonary exam was unremarkable in clinic.</p></div><div><p>Initial workup included normal basic labs, a BNP of 180, and an EKG with LVH, RBBB, and LAFB. The hypertrophy and extent of conduction disease prompted his PCP to get a TTE, which showed: “Moderate concentric left ventricular hypertrophy with ejection fraction 50-55%. Biatrial enlargement. Homogenous speckled appearance of left ventricle, coupled with left ventricular</p></div><div><p>hypertrophy is strongly suggestive for infiltrative disease.”</p></div><div><p>Workup of infiltrative cardiac disease</p></div><div><ul><li data-line="0">Infiltrative disease fits into the broader category of restrictive cardiomyopathy, classically identified due to ventricular wall thickening and biatrial enlargement (due to elevated filling pressures).</li><li data-line="1">Within restrictive CM are familial disorders, infiltrative diseases (amyloid, sarcoid, fat), storage diseases (hemochromatosis, Fabry, glycogen storage diseases), and a host of other causes (drugs, toxins, radiation, metastatic disease).</li><li data-line="2">When considering the most common causes of new restrictive CM in an adult, we are mostly discussing amyloidosis, sarcoidosis, and hemochromatosis.</li><li data-line="3">Workup should first be aimed at assessing for these three conditions.</li></ul></div><div><p>The gold standard for confirming infiltrative disease is endomyocardial biopsy (EMB). However,</p></div><div><p>EMB is a highly invasive test, and the most common adult conditions above can initially</p></div><div><p>be worked up non-invasively.</p></div><div><p>Labs:</p></div><div><ul><li data-line="0"><ul><li data-line="0">Iron studies (hemochromatosis)</li></ul></li><li data-line="1"><ul><li data-line="1">SPEP, Serum free light chains (AL amyloidosis)</li></ul></li><li data-line="2"><ul><li data-line="2">BNP, troponin (prognostic in infiltrative</li></ul></li><li data-line="3">cardiac disease)</li></ul></div><div><p>Imaging:</p></div><div><ul><li data-line="0"><ul><li data-line="0">The first step to confirm infiltrative or storage disease is cardiac imaging, most commonly cardiac MRI. This can confirm the diagnosis and may identify distinguishing</li></ul></li><li data-line="1">features between amyloid, sarcoid, and hemochromatosis.</li><li data-line="2"><ul><li data-line="2">CT chest (evaluating for extracardiacmanifestations of sarcoidosis)</li></ul></li></ul></div><div><p>Tissue:</p></div><div><ul><li data-line="0"><ul><li data-line="0">Fat pad biopsy (AL amyloidosis)</li></ul></li><li data-line="1"><ul><li data-line="1">EMB (gold standard, most invasive)</li></ul></li></ul></div><div><p>Our patient had the above lab testing with normal iron studies and SPEP showing monoclonal gammopathy with IgG kappa paraprotein, and K/L ratio of 2.31. His chest CT was negative for extracardiac signs of sarcoidosis. Fat pad biopsy and cardiac MRI are pending.</p></div><div><p>Even without cardiac MRI or fat pad biopsy, based on the patient's history of carpal tunnel, SPEP, and negative CT, the cardiology consult clinic felt the patient most likely has cardiac amyloid. How did we get to this conclusion?</p></div><div><p>Cardiac amyloidosis</p></div><div><p>Amyloidosis is a heterogenous group of disorders that result from the deposition of a misfolded</p></div><div><p>protein. The type of protein determines the deposition pattern and therefore the clinical manifestations. While amyloidosis can appear in numerous forms, it turns out that only two subtypes of amyloid account for 95% of cardiac disease – AL amyloid and ATTR amyloid.</p></div><div><p>AL (lightchain) amyloid is associated with plasma cell dyscrasias (such as multiple myeloma,</p></div><div><p>Waldenstrom’s, and MGUS). It has a much broader range of clinical manifestations, including heart, kidney, liver, and skin. Due to deposition in soft tissues, this can be diagnosed with fat pad biopsy. In our patient’s case, his monoclonal gammopathy and slightly elevated K/L ratio make AL amyloid a possibility.</p></div><div><p>ATTR amyloid describes deposition of transthyretin (TTR), either due to familial mutation or wild type disease. ATTR amyloid has a much more specific predisposition for cardiac and carpal tunnel tissues. In fact, wild-type TTR deposits are found in about 1/3 of older adults undergoing carpal tunnel decompression! Based on our patient’s apparent isolated cardiac and carpal tunnel involvement, suspicion is even higher for ATTR amyloidosis.</p></div><div><p><strong>Summary</strong></p></div><div><ol><li data-line="0"><p>Workup for restrictive cardiomyopathy in adults focuses on three big causes: amyloidosis, sarcoidosis, and hemochromatosis; while endomyocardial biopsy is the gold standard, non-invasive workup (including cardiac MRI) can often distinguish these diseases.</p></li><li data-line="2"><p>Amyloidosis is a heterogenous group of disorders that result from the deposition of a misfolded protein. While amyloidosis can appear in numerous forms, it turns out that only two subtypes of amyloid account for 95% of cardiac disease – AL amyloid and ATTR amyloid.</p></li><li data-line="4"><p>ATTR amyloid has a much more specific predisposition for cardiac and carpal tunnel tissues; in an older patient with dyspnea and bilateral carpal tunnel, consider ATTR amyloid!</p></li></ol></div><div><p>**<br>**</p></div><div><p><strong>Name two diseases that may be associated with temporal arteritis and thus mimic giant-cell arteritis.</strong></p></div><div><p>Vasculitis such as aortitis and periaortitis, sometimes concurrent with retroperitoneal fibrosis, is a potential manifestation of IgG4-related disease, and temporal arteritis has been reported occasionally. In rare cases, sarcoidosis can be complicated by systemic vasculitis affecting small, medium, or large vessels. In fact, sarcoidosis-associated vasculitis involving the extracranial arteries (e.g., temporal arteries) with resultant headache and jaw claudication has been reported.</p></div><div><p><strong>What causes primary amyloidosis?</strong></p></div><div><p>Primary amyloidosis is a plasma-cell dyscrasia caused by deposition of protein fragments derived from abnormal immunoglobulin light chains. The mean age at diagnosis is 63 years, and men are affected more often than women. In most patients with primary amyloidosis, the amyloidogenic light chains are produced by low-level expansion of an indolent B-cell clone that arises in the context of monoclonal gammopathy of undetermined significance. In some patients, the disease occurs in association with multiple myeloma, lymphoplasmacytic lymphoma (formerly called Waldenström’s macroglobulinemia), or non-Hodgkin’s lymphoma.</p></div><div><p><strong>What are some of the manifestations of primary amyloidosis?</strong></p></div><div><p>The most frequently affected organs are the kidneys (leading to nephrotic proteinuria) and the heart (causing pump failure). Patients may also have peripheral and autonomic neuropathy, joint and soft-tissue infiltration (e.g., extraocular muscle enlargement), deposits in the lacrimal gland and salivary gland, gastrointestinal dysmotility, skin lesions (e.g., papules and ecchymosis), lymphadenopathy, splenomegaly, liver disease, respiratory manifestations (e.g., lung nodules), and bleeding diathesis. Liver involvement, which occurs in approximately 20 to 30% of cases of primary amyloidosis, may manifest as elevated aminotransferase levels, cholestasis, and hepatomegaly. Computed tomography of the liver may show areas of parenchymal hypoattenuation in patients with clinically significant amyloid deposition. Furthermore, amyloid fibrils have an affinity for calcium, and imaging studies can show calcified deposits in different organs, including the liver and lymph nodes.</p></div><div><p><strong>How is primary amyloidosis diagnosed?</strong></p></div><div><p>The diagnosis of amyloidosis requires the identification of amyloid fibrils in tissue. On microscopic examination, these fibrils show a pathognomonic apple-green birefringence under polarized light after Congo red staining. If amyloid material is identified, the next steps are to determine the type of amyloid with the use of immunohistochemical studies or laser capture microdissection followed by mass spectrometry, as well as to assess the extent and severity of the disease. Where available, imaging with radioiodinated serum amyloid P component can be used to measure the burden of disease and monitor the response to treatment.</p></div><div><p><strong>Sarcoidosis</strong></p></div><div><p>Sarcoidosis is an immune-mediated disorder of unknown cause that can affect all racial groups. It can occur anytime in adulthood but usually develops before 50 years of age. The disease is characterized by noncaseating granulomatous inflammation that can involve any organ.4 Ap- proximately 90% of patients present with intra- thoracic abnormalities such as hilar lymphade- nopathy and interstitial lung disease.5 In approximately 30% of cases, extrathoracic man- ifestations occur, most commonly involving the joints (e.g., arthralgias), the eyes (e.g., uveitis), and the skin (e.g., erythema nodosum).5 Consti- tutional symptoms are frequently reported. Sar- coidosis can also affect the central and periph- eral nervous system, extraocular orbital structures (e.g., lacrimal glands and extraocular muscles), liver, spleen, heart, gastrointestinal tract, kid- neys, and calcium metabolism.5 In rare cases, sarcoidosis can be complicated by systemic vascu- litis affecting small, medium, or large vessels.6 In fact, sarcoidosis-associated vasculitis involving the extracranial arteries (e.g., temporal arteries) with resultant headache and jaw claudication has been reported.7-9</p></div><div><p>This patient could have sarcoidosis with an atypical presentation that mimics giant-cell arte- ritis, in addition to infiltration of the lacrimal glands, extraocular muscles, lymph nodes, and liver. Autopsy studies have shown that liver in- volvement occurs in most patients with sarcoid- osis but becomes clinically significant in ap- proximately 10 to 30% of patients.10 Hepatitis associated with sarcoidosis sometimes causes parenchymal hypoattenuation and leads to dys- trophic calcification, findings that are seen in this patient. Arguing against the possibility of sarcoidosis, however, is the fact that this patient has a single prominent right hilar lymph node measuring 10 mm in diameter; in patients with sarcoidosis, hilar lymphadenopathy tends to be associated with larger, multiple, and bilateral lymph nodes.4 Measurement of angiotensin- converting enzyme and 1,25-dihydroxyvitamin D levels could be helpful in this case; elevated levels would support but not confirm the diag- nosis of sarcoidosis. The most appropriate con</p></div><div><p>firmatory test would be a tissue biopsy (e.g., lymph node, lacrimal gland, or liver biopsy), with the specimen showing noncaseating granulomas.</p></div><div><p><strong>IgG4-Related Disease</strong></p></div><div><p>IgG4-related disease is a multisystem fibroin- flammatory disease that has been increasingly recognized over the past decade.11 Men are af- fected more frequently than women, and the age at onset is typically between 50 and 60 years. Lesions associated with IgG4-related disease are characterized by lymphoplasmacytic infiltrates and storiform fibrosis.11 The most commonly affected organs are the pancreas (i.e., autoim- mune pancreatitis type 1), the hepatobiliary sys- tem (e.g., sclerosing cholangitis), and the salivary and lacrimal glands.12 Other possible manifesta- tions include lymphadenitis, dermatitis, thyroid- itis, pachymeningitis, hypophysitis, pericarditis, tubulointerstitial nephritis, lung parenchymal masses, orbital pseudotumor formation, and extraocular muscle involvement.12 Vasculitis such as aortitis with periaortitis, sometimes concur- rent with retroperitoneal fibrosis, is another potential manifestation of IgG4-related disease,13 and temporal arteritis has been reported occa- sionally.14,15</p></div><div><p>Patients with IgG4-related disease present with synchronous involvement of three organs, on average. The main clinical phenotypes of or- gan involvement are hepatopancreatobiliary dis- ease, retroperitoneal fibrosis or aortitis, disease limited to the head and neck, and classic Miku- licz syndrome with systemic features.16 Patients with disease limited to the head and neck or with classic Mikulicz syndrome with systemic features tend to have the highest serum IgG4 levels and frequently have inflammation of the lacrimal glands (in 50 to 60% of cases), salivary glands (50 to 80%), and lymph nodes (30 to 70%); however, these two clinical phenotypes are not frequently associated with involvement of the liver (in &lt;5% of cases) or biliary tree (1 to 30%).16</p></div><div><p>Although this patient could have an uncom- mon form of IgG4-related disease, several fea- tures of his presentation are not consistent with this diagnosis. First, patients with IgG4-related disease tend to have inflammation of both the lacrimal glands and the salivary glands bilater- ally,11,16,17 whereas this patient has unilateral lacrimal gland enlargement and no obvious sali- vary gland disease. Second, many patients with</p></div><div><p>IgG4-related disease have pancreatic involve- ment,11,16 which is absent in this patient. Third, most patients with IgG4-related disease have normal serum inflammatory marker levels and increased serum IgG4 levels (&gt;135 mg per deci- liter),18 especially in the presence of multiorgan disease and infiltration of exocrine glands, and these laboratory findings are absent in this pa- tient. Fourth, this patient has lymph node and liver calcifications, which are not commonly observed in patients with IgG4-related disease. Finally, reports of IgG4-related disease with cra- nial manifestations that mimic giant-cell arteri- tis are rare.</p></div><div><p><strong>Systemic Amyloidosis</strong></p></div><div><p>Systemic amyloidosis is a rare disease that re- sults from protein misfolding and aggregation into highly ordered fibrils that deposit in tissues and cause progressive organ damage. Amyloido- sis can occur in the presence of an abnormal protein (e.g., primary amyloidosis, also known as amyloid light-chain [AL] amyloidosis), in as- sociation with excess abundance of a normal protein (e.g., secondary amyloidosis, also known as amyloid A [AA] amyloidosis), and for unclear reasons (e.g., senile systemic amyloidosis).19</p></div><div><p>Primary amyloidosis is a plasma-cell dyscra- sia caused by deposition of protein fragments derived from abnormal immunoglobulin light chains.19 The mean age at diagnosis is 63 years, and men are affected more often than women.19 In most patients with primary amyloidosis, the amyloidogenic light chains are produced by low- level expansion of an indolent B-cell clone that arises in the context of monoclonal gammopa- thy of undetermined significance. In some pa- tients, the disease occurs in association with multiple myeloma, Waldenström’s macroglobu- linemia, or non-Hodgkin’s lymphoma. The most frequently affected organs are the kidneys (lead- ing to nephrotic proteinuria) and the heart (causing pump failure). Patients may also have peripheral and autonomic neuropathy, joint and soft-tissue infiltration (e.g., extraocular muscle enlargement),20 deposits in the lacrimal glands21 and salivary glands, gastrointestinal dysmotility, skin lesions (e.g., papules and ecchymosis), lymphadenopathy,22 splenomegaly, liver disease, respiratory manifestations (e.g., lung nodules), and bleeding diathesis.19 Liver involvement, which occurs in approximately 20 to 30% of cases of primary amyloidosis,23 may manifest as elevated aminotransferase levels, cholestasis, and hepato- megaly. CT of the liver may show areas of paren- chymal hypoattenuation in patients with clinical- ly significant amyloid deposition.24 Furthermore, amyloid fibrils have an affinity for calcium, and imaging studies can show calcified deposits in different organs, including the liver24 and lymph nodes,25 findings similar to those seen in this patient.</p></div><div><p>Primary amyloidosis can affect any organ, including the arteries, except for the brain. In fact, several cases of primary amyloidosis with cranial features similar to those of giant-cell arteritis have been reported.20,26-31 The diagnosis of primary amyloidosis may well explain this patient’s constellation of clinical manifestations, including the liver involvement with character- istic findings on imaging (parenchymal hypo- attenuation and calcification), lymphadenopathy, lacrimal gland involvement, extraocular muscle enlargement, and a syndrome resembling giant- cell arteritis, with prominent temporal arteries, temporal headache, jaw claudication, and tran- sient vision loss. In cases of amyloidosis mim- icking giant-cell arteritis, vision loss is presum- ably caused by transient or permanent occlusion of the posterior ciliary arteries or the retinal arteries.20,29,32 In addition, this patient reports lateral hip soreness and symptoms suggestive of stenosing flexor tenosynovitis (trigger finger) of the right first finger, which could be caused by amyloid infiltration in soft tissues. Finally, the increase in the erythrocyte sedimentation rate is disproportionate to the increase in the C-reactive protein level, a finding that perhaps reflects the presence of paraproteinemia, which is seen in more than 90% of patients with primary amy- loidosis.</p></div><div><p>The diagnosis of amyloidosis requires the identification of amyloid fibrils in tissue. On microscopic examination, these fibrils show a pathognomonic apple-green birefringence under polarized light after Congo red staining.19 To establish the diagnosis in this case, I would recommend performing immunoelectrophoresis and quantifying free light chains in blood and urine to look for a monoclonal component, and most important, performing a biopsy to confirm the presence of amyloid deposits. A fat-pad bi- opsy is simple to perform and has a relatively high yield for the diagnosis of systemic primary&nbsp;amyloidosis. Other tissues that could be sampled in this patient include the rectal or lip mucosa, left lacrimal gland, temporal arteries, liver, and abdominal lymph nodes. Because amyloidosis is often associated with hemostatic defects, less invasive procedures are generally recommended as an initial diagnostic approach. If amyloid material is identified, the next steps are to deter- mine the type of amyloid with the use of im- munohistochemical studies or laser-capture mi- crodissection followed by mass spectrometry, as well as to assess the extent and severity of the disease.19 Where available, imaging with radioio- dinated serum amyloid P component can be used to measure the burden of disease and monitor the response to treatment.33 If the diag- nosis of primary amyloidosis is confirmed in this patient, I would also recommend a bone marrow biopsy to rule out multiple myeloma, which occurs in 10 to 15% of patients with pri- mary amyloidosis.</p></div><div><p>For the treatment of pri- mary amyloidosis with hepatic involvement, the patient received daratumumab, bortezomib, and dexamethasone. Daratumumab is a human IgG1k monoclonal antibody that targets CD38, a cell- surface glycoprotein highly expressed on plasma cells; bortezomib is a proteasome inhibitor; and dexamethasone is a glucocorticoid. From initia- tion to completion of three cycles of therapy, the alkaline phosphatase level decreased from 1764 U</p></div><div><p>per liter to 939 U per liter, the alanine amino- transferase level from 457 U per liter to 190 U per liter, the aspartate aminotransferase level from 435 U per liter to 121 U per liter, and the serum level of kappa free light chains from 1271.4 mg per liter to 78.3 mg per liter.</p></div><div><p>The patient underwent a total of four cycles of therapy and has not had any clinically sig- nificant side effects. He is now working full time and reports that he feels well.</p></div><div><p>&nbsp;<a class="internal-link is-unresolved" data-href="../_resources/NEJM CPC primary amyloidosis.pdf" href="../_resources/NEJM CPC primary amyloidosis.pdf" target="_self" rel="noopener">NEJM CPC primary amyloidosis.pdf</a></p></div><div class="mod-footer"></div></div></div></div><div class="sidebar-right sidebar"><div class="sidebar-gutter"><div class="clickable-icon sidebar-collapse-icon"><svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><path d="M21 3H3C1.89543 3 1 3.89543 1 5V19C1 20.1046 1.89543 21 3 21H21C22.1046 21 23 20.1046 23 19V5C23 3.89543 22.1046 3 21 3Z"></path><path d="M10 4V20"></path><path d="M4 7H7"></path><path d="M4 10H7"></path><path d="M4 13H7"></path></svg></div></div><div class="sidebar-container"><div class="sidebar-sizer"><div class="sidebar-content-positioner"><div class="sidebar-content"><div class="graph-view-wrapper"><div class="sidebar-section-header">Interactive Graph</div><div class="graph-view-placeholder"><div class="graph-view-container"><div class="graph-icon graph-expand" role="button" aria-label="Expand" data-tooltip-position="top"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon"><line x1="7" y1="17" x2="17" y2="7"></line><polyline points="7 7 17 7 17 17"></polyline></svg></div><canvas id="graph-canvas" width="512px" height="512px"></canvas></div></div></div><div class="tree-container outline-tree" data-depth="0"><div class="tree-header"><span class="sidebar-section-header">Table Of Contents</span><button class="clickable-icon collapse-tree-button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"></svg></button></div><div class="tree-scroll-area"></div></div></div></div></div></div></div></div></body></html>